JP2019524888A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019524888A5 JP2019524888A5 JP2019530367A JP2019530367A JP2019524888A5 JP 2019524888 A5 JP2019524888 A5 JP 2019524888A5 JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019530367 A JP2019530367 A JP 2019530367A JP 2019524888 A5 JP2019524888 A5 JP 2019524888A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- effective amount
- therapeutically effective
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 94
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 46
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 30
- 208000032839 leukemia Diseases 0.000 claims description 26
- 201000005787 hematologic cancer Diseases 0.000 claims description 14
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 14
- 102000011690 Adiponectin Human genes 0.000 claims description 12
- 108010076365 Adiponectin Proteins 0.000 claims description 12
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical class [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 10
- 239000000651 prodrug Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 8
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 8
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 208000034578 Multiple myelomas Diseases 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 8
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims description 8
- 208000007452 Plasmacytoma Diseases 0.000 claims description 8
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 8
- 230000003442 weekly effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000002354 daily effect Effects 0.000 claims 14
- 230000003203 everyday effect Effects 0.000 claims 4
- 230000002489 hematologic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 57
- NMRWDFUZLLQSBN-UHFFFAOYSA-N 2,4-dichloro-n-(3,5-dichloro-4-quinolin-3-yloxyphenyl)benzenesulfonamide Chemical compound ClC1=CC(Cl)=CC=C1S(=O)(=O)NC(C=C1Cl)=CC(Cl)=C1OC1=CN=C(C=CC=C2)C2=C1 NMRWDFUZLLQSBN-UHFFFAOYSA-N 0.000 description 4
- 0 C*C(C1)C(C)NC*2C1=CC=CC2 Chemical compound C*C(C1)C(C)NC*2C1=CC=CC2 0.000 description 4
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960005095 pioglitazone Drugs 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022091309A JP2022116304A (ja) | 2016-08-18 | 2022-06-06 | 血液がんの治療のためのＰＰＡＲγアゴニスト |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376749P | 2016-08-18 | 2016-08-18 | |
| US62/376,749 | 2016-08-18 | ||
| PCT/US2017/047578 WO2018035446A1 (en) | 2016-08-18 | 2017-08-18 | PPARγ AGONIST FOR TREATMENT OF BLOOD CANCERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091309A Division JP2022116304A (ja) | 2016-08-18 | 2022-06-06 | 血液がんの治療のためのＰＰＡＲγアゴニスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524888A JP2019524888A (ja) | 2019-09-05 |
| JP2019524888A5 true JP2019524888A5 (enExample) | 2020-10-01 |
Family
ID=61197183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530367A Pending JP2019524888A (ja) | 2016-08-18 | 2017-08-18 | 血液がんの治療のためのＰＰＡＲγアゴニスト |
| JP2022091309A Withdrawn JP2022116304A (ja) | 2016-08-18 | 2022-06-06 | 血液がんの治療のためのＰＰＡＲγアゴニスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022091309A Withdrawn JP2022116304A (ja) | 2016-08-18 | 2022-06-06 | 血液がんの治療のためのＰＰＡＲγアゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210379049A1 (enExample) |
| EP (1) | EP3500268A4 (enExample) |
| JP (2) | JP2019524888A (enExample) |
| KR (1) | KR20190064573A (enExample) |
| CN (1) | CN110461329A (enExample) |
| AU (1) | AU2017313839A1 (enExample) |
| BR (1) | BR112019003130A2 (enExample) |
| CA (1) | CA3034258A1 (enExample) |
| EA (1) | EA201990512A1 (enExample) |
| MX (1) | MX2019001979A (enExample) |
| SG (2) | SG10202101501PA (enExample) |
| WO (1) | WO2018035446A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249847A1 (zh) | 2015-03-09 | 2018-11-16 | Intekrin Therapeutics, Inc. | 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| KR20200036808A (ko) | 2017-04-03 | 2020-04-07 | 코히러스 바이오사이언시스, 인크. | 진행성 핵상 마비 치료를 위한 PPARγ 작용제 |
| WO2020243058A1 (en) * | 2019-05-30 | 2020-12-03 | Coherus Biosciences, Inc. | Compositions and methods to treat cancer |
| JP2022104746A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗がん剤 |
| JP2022104747A (ja) * | 2020-12-29 | 2022-07-11 | 国立研究開発法人国立がん研究センター | 抗ウイルス剤 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3018186B1 (ja) * | 1999-03-09 | 2000-03-13 | 大阪大学長 | 抗炎症剤、単球系細胞の増殖抑制剤 |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| JP2010265216A (ja) * | 2009-05-14 | 2010-11-25 | Takeda Chem Ind Ltd | 複素環化合物 |
| SG11201505944QA (en) * | 2013-01-30 | 2015-08-28 | Intekrin Therapeutics Inc | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS |
| PL3468604T3 (pl) * | 2016-06-08 | 2021-07-12 | Support-Venture Gmbh | Kombinacje farmaceutyczne do leczenia nowotworu złośliwego |
-
2017
- 2017-08-18 AU AU2017313839A patent/AU2017313839A1/en not_active Abandoned
- 2017-08-18 JP JP2019530367A patent/JP2019524888A/ja active Pending
- 2017-08-18 EP EP17842202.8A patent/EP3500268A4/en not_active Withdrawn
- 2017-08-18 KR KR1020197007705A patent/KR20190064573A/ko not_active Ceased
- 2017-08-18 MX MX2019001979A patent/MX2019001979A/es unknown
- 2017-08-18 SG SG10202101501PA patent/SG10202101501PA/en unknown
- 2017-08-18 WO PCT/US2017/047578 patent/WO2018035446A1/en not_active Ceased
- 2017-08-18 BR BR112019003130-8A patent/BR112019003130A2/pt not_active IP Right Cessation
- 2017-08-18 US US16/326,018 patent/US20210379049A1/en not_active Abandoned
- 2017-08-18 CN CN201780063382.4A patent/CN110461329A/zh active Pending
- 2017-08-18 CA CA3034258A patent/CA3034258A1/en active Pending
- 2017-08-18 EA EA201990512A patent/EA201990512A1/ru unknown
- 2017-08-18 SG SG11201901320WA patent/SG11201901320WA/en unknown
-
2022
- 2022-06-06 JP JP2022091309A patent/JP2022116304A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016226006B2 (en) | Method of treatment with tradipitant | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2020117553A5 (enExample) | ||
| WO2017042944A1 (ja) | フィラデルフィア染色体陽性（Ｐｈ＋）急性リンパ性白血病（ＡＬＬ）の治療薬又は治療方法 | |
| JP2018516936A5 (enExample) | ||
| JP2014513705A (ja) | 進行性固形腫瘍の治療方法 | |
| JP2014144962A5 (enExample) | ||
| JP2023548055A5 (enExample) | ||
| JP2015517523A5 (enExample) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2024542984A5 (enExample) | ||
| CN104039148A (zh) | 组合als疗法 | |
| JP2018526440A (ja) | 免疫系を刺激するためのインドール化合物の使用 | |
| JP2014534229A5 (enExample) | ||
| US12370202B2 (en) | Methods and compositions for inhibiting the NLRP3 inflammasome and/or LON protease | |
| JP2021502379A5 (enExample) | ||
| JP2023513298A5 (enExample) | ||
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JP2023011549A5 (enExample) | ||
| FI3359572T3 (fi) | Menetelmä multippeliskleroosin hoitamiseksi | |
| JP2022058873A5 (enExample) |